stat3 inhibitor flll32 Search Results


90
MedKoo Inc stat3 inhibitor flll32
Stat3 Inhibitor Flll32, supplied by MedKoo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+inhibitor+flll32/stat3+phosphorylation+inhibitor+flll32/pmc04552937__gutjnl___2014___307020___s1-14-2-8
Average 90 stars, based on 1 article reviews
stat3 inhibitor flll32 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Medco Instruments stat3 inhibitor flll32
a Serum IL-6 and IL-8 concentration levels in GC patients compared to healthy donors. b Correlations between the proportions of peripheral blood CD45 + CD33 low CD11b dim myeloid cells or serum arginase I concentration and IL-6 or IL-8 serum concentrations in GC patients. c Arginase I expression and production in CD33 low CD11b dim myeloid cells exposed to recombinant IL-6 and/or IL-8, or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs as analyzed by western blot and ELISA, respectively. d Arginase I expression in CD45 + CD33 low CD11b dim myeloid cells exposed to 50% GC patient serum in the presence or absence of <t>FLLL32</t> <t>(STAT3</t> phosphorylation inhibitor), Wortmannin (PI3K inhibitor), or SB203580 (MAPK inhibitor; top panel). AKT and p-AKT expression levels in CD45 + CD33 low CD11b dim myeloid cells exposed to IL-6 and/or IL-8 (middle panel), or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs (bottom panels) as analyzed by western blot. * p < 0.05; ** p < 0.01, and n.s, p > 0.05. ARG I arginase I
Stat3 Inhibitor Flll32, supplied by Medco Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+inhibitor+flll32/stat3+inhibitor+flll32/pmc06037756-152-5-8
Average 90 stars, based on 1 article reviews
stat3 inhibitor flll32 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

94
MedChemExpress flll32
a Serum IL-6 and IL-8 concentration levels in GC patients compared to healthy donors. b Correlations between the proportions of peripheral blood CD45 + CD33 low CD11b dim myeloid cells or serum arginase I concentration and IL-6 or IL-8 serum concentrations in GC patients. c Arginase I expression and production in CD33 low CD11b dim myeloid cells exposed to recombinant IL-6 and/or IL-8, or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs as analyzed by western blot and ELISA, respectively. d Arginase I expression in CD45 + CD33 low CD11b dim myeloid cells exposed to 50% GC patient serum in the presence or absence of <t>FLLL32</t> <t>(STAT3</t> phosphorylation inhibitor), Wortmannin (PI3K inhibitor), or SB203580 (MAPK inhibitor; top panel). AKT and p-AKT expression levels in CD45 + CD33 low CD11b dim myeloid cells exposed to IL-6 and/or IL-8 (middle panel), or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs (bottom panels) as analyzed by western blot. * p < 0.05; ** p < 0.01, and n.s, p > 0.05. ARG I arginase I
Flll32, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/stat3+inhibitor+flll32/FLLL32/custom%40hy-100544%4034453123
Average 94 stars, based on 1 article reviews
flll32 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


a Serum IL-6 and IL-8 concentration levels in GC patients compared to healthy donors. b Correlations between the proportions of peripheral blood CD45 + CD33 low CD11b dim myeloid cells or serum arginase I concentration and IL-6 or IL-8 serum concentrations in GC patients. c Arginase I expression and production in CD33 low CD11b dim myeloid cells exposed to recombinant IL-6 and/or IL-8, or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs as analyzed by western blot and ELISA, respectively. d Arginase I expression in CD45 + CD33 low CD11b dim myeloid cells exposed to 50% GC patient serum in the presence or absence of FLLL32 (STAT3 phosphorylation inhibitor), Wortmannin (PI3K inhibitor), or SB203580 (MAPK inhibitor; top panel). AKT and p-AKT expression levels in CD45 + CD33 low CD11b dim myeloid cells exposed to IL-6 and/or IL-8 (middle panel), or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs (bottom panels) as analyzed by western blot. * p < 0.05; ** p < 0.01, and n.s, p > 0.05. ARG I arginase I

Journal: Cell Death & Disease

Article Title: CD45 + CD33 low CD11b dim myeloid-derived suppressor cells suppress CD8 + T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer

doi: 10.1038/s41419-018-0803-7

Figure Lengend Snippet: a Serum IL-6 and IL-8 concentration levels in GC patients compared to healthy donors. b Correlations between the proportions of peripheral blood CD45 + CD33 low CD11b dim myeloid cells or serum arginase I concentration and IL-6 or IL-8 serum concentrations in GC patients. c Arginase I expression and production in CD33 low CD11b dim myeloid cells exposed to recombinant IL-6 and/or IL-8, or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs as analyzed by western blot and ELISA, respectively. d Arginase I expression in CD45 + CD33 low CD11b dim myeloid cells exposed to 50% GC patient serum in the presence or absence of FLLL32 (STAT3 phosphorylation inhibitor), Wortmannin (PI3K inhibitor), or SB203580 (MAPK inhibitor; top panel). AKT and p-AKT expression levels in CD45 + CD33 low CD11b dim myeloid cells exposed to IL-6 and/or IL-8 (middle panel), or 50% GC patient serum in the presence or absence of IL-6 and/or IL-8 neutralizing abs (bottom panels) as analyzed by western blot. * p < 0.05; ** p < 0.01, and n.s, p > 0.05. ARG I arginase I

Article Snippet: Drug inhibitors studies involved the STAT3 inhibitor FLLL32 (Medco Biosciences), PI3K inhibitor Wortmannin, and MAPK inhibitor SB203580 (Calbiochem).

Techniques: Concentration Assay, Expressing, Recombinant, Western Blot, Enzyme-linked Immunosorbent Assay